Huons Decides to Merge with Subsidiary Huons Lab... 24.2% New Shares Dilution, Long-term R&D Synergy Expected
Merger method: Huons (KOSDAQ listed) absorbs unlisted subsidiary Huons Lab. Huons survives; no change in management.
Purpose: Strengthen new drug/biosimilar pipeline to leap into global pharma/biotech from generic-centric business.
Merger ratio: 1 Huons share for 0.4256893 Huons Lab share. Huons merger price 34,062 won (market-based), Huons Lab price 14,500 won (intrinsic value).
New shares: 3,825,327 common shares issued (24.2% dilution relative to outstanding 11,979,665 shares).
Huons Lab financials: As of end-2025, total equity -1.8B won, net loss 10.2B won. Liabilities exceed assets; weak financial position.
Shareholder impact: Short-term dilution and increased R&D costs. Long-term synergy and cost savings expected to increase enterprise value.
Appraisal rights: Buyout price 32,886 won. Dissenting shareholders may exercise after written notice before shareholder meeting. Merger can be cancelled if buyout claims exceed 30B won.
[AI Comprehensive Analysis]Huons' merger with Huons Lab involves short-term dilution (24.2%) and financial distress (negative equity) for existing shareholders, posing investment risks. However, securing new drug pipelines and vertical integration may provide long-term growth drivers. Future securities report and shareholder meeting results should be monitored.
KOSDAQ Filing Information
Filing: [Correction of Description] Report On Major Matters (Decision On Company Merger)